Munich - Delayed Quote EUR

Omeros Corp (3O8.MU)

6.20

-0.07

(-1.04%)

As of 8:08:07 AM GMT+2. Market Open.

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program

SEATTLE, April 10, 2025--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros’ OncotoX program for AML consists of proprietary targeted,

Business Wire 13 days ago

OMER
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

SEATTLE, April 08, 2025--Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur at the European Congress on Infectious Diseases 2025 in Rome, Italy on Monday, April 14. The plenum presentation, titled Augmenting cytotoxicity of pathogen-specific antibodies which initiate complement activation independent of the classical pathway, will be delivered by Prof. Wilhelm Schwaeble, Ph

Business Wire 15 days ago

OMER
Q4 2024 Omeros Corp Earnings Call

Q4 2024 Omeros Corp Earnings Call

Thomson Reuters StreetEvents 22 days ago

OMER
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ...

Despite a significant net loss, Omeros Corp (OMER) focuses on strategic partnerships and a promising pipeline to bolster its financial position and future growth.

GuruFocus.com 23 days ago

OMER
Omeros: Q4 Earnings Snapshot

SEATTLE (AP) — Omeros Corporation OMER on Monday reported a loss of $31.4 million in its fourth quarter. The Seattle-based company said it had a loss of 54 cents per share. Losses, adjusted to account for discontinued operations, came to 63 cents per share.

Associated Press Finance 23 days ago

OMER
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

SEATTLE, March 31, 2025--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include:

Business Wire 23 days ago

OMER
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

SEATTLE, March 26, 2025--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Business Wire 28 days ago

OMER
Omeros to activate site for Phase III programme of zaltenibart for PNH

The Phase III programme will involve 120 clinical investigative sites across 30 nations.

Clinical Trials Arena 30 days ago

OMER
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

SEATTLE, March 21, 2025--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart (OMS906) is Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement. Zaltenibart inhibits the intravascular hemolysis treated by C5 inhibitors as well as the extravascular hemolysis

Business Wire last month

OMER
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder

SEATTLE, March 13, 2025--Omeros Corporation (Nasdaq: OMER) today announced that it has received a funding commitment from the National Institute on Drug Abuse (NIDA) for the upcoming year (April 1, 2025 through March 31, 2026) in the amount of $4.02 million for clinical development of its lead orally administered phosphodiesterase 7 (PDE7) inhibitor OMS527 to treat cocaine use disorder (CUD), reducing or eliminating craving and relapse in patients with CUD. This grant will fund the Phase 1b clin

Business Wire last month

OMER
Omeros announces results for narsoplimab expanded access program

Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation. These latest analyses, conducted by an independent statistical group, comprise multiple survival comparisons between narsop

TipRanks last month

OMER
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

SEATTLE, February 20, 2025--Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). These latest analyses, conducted

Business Wire 2 months ago

OMER
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

SEATTLE, February 14, 2025--Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.

Business Wire 2 months ago

OMER
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

SEATTLE, February 10, 2025--Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 12-15, 2025 in Honolulu, Hawaii.

Business Wire 2 months ago

OMER
Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company

Key Insights Significant control over Omeros by retail investors implies that the general public has more power to...

Simply Wall St. 2 months ago

OMER
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

SEATTLE, January 16, 2025--Omeros Corporation (Nasdaq: OMER) today announced statistical sensitivity analysis results related to the primary endpoint analysis for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation. The sensitivity analyses, conduc

Business Wire 3 months ago

OMER
When Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)?

With the business potentially at an important milestone, we thought we'd take a closer look at Omeros Corporation's...

Simply Wall St. 3 months ago

OMER
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges

Across various trials, narsoplimab has shown no safety signals of concern.

GuruFocus.com 4 months ago

OMER
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

SEATTLE, December 19, 2024--Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). T

Business Wire 4 months ago

OMER
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going to take a look at where Omeros Corporation (NASDAQ:OMER) stands against other stocks under Jim Cramer’s lightning rounds’ spotlight. Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following […]

Insider Monkey 4 months ago

OMER

Performance Overview

Return	3O8.MU	S&P 500 (^GSPC)
YTD	-44.60%	-8.60%
1-Year	+113.23%	+6.00%
3-Year	+61.00%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Omeros Corp (3O8.MU)

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Q4 2024 Omeros Corp Earnings Call

Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ...

Omeros: Q4 Earnings Snapshot

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Omeros to activate site for Phase III programme of zaltenibart for PNH

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder

Omeros announces results for narsoplimab expanded access program

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

When Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)?

Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges

Performance Overview